
Peter Francis Rebeiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8115549/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Who Is Not Linking to HIV Care in Tennessee — the Benefits of an Intersectional Approach. Journal of Racial and Ethnic Health Disparities, 2022, 9, 849-855.	3.2	2
2	A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. Clinical Infectious Diseases, 2022, 74, 973-982.	5.8	9
3	Projecting the age-distribution of men who have sex with men receiving HIV treatment in the United States. Annals of Epidemiology, 2022, 65, 46-55.	1.9	8
4	The shifting age distribution of people with HIV using antiretroviral therapy in the United States. Aids, 2022, 36, 459-471.	2.2	20
5	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. Clinical Infectious Diseases, 2022, 75, 867-874.	5.8	10
6	Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America. The Lancet Regional Health Americas, 2022, 8, 100173.	2.6	2
7	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. Aids, 2022, 36, 277-286.	2.2	5
8	Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study. The Lancet Regional Health Americas, 2022, 8, 100175.	2.6	0
9	The Impact of COVID-19 on the HIV Care Continuum in a Large Urban Southern Clinic. AIDS and Behavior, 2022, 26, 2825-2829.	2.7	20
10	Individual, community, and structural factors associated with linkage to HIV care among people diagnosed with HIV in Tennessee. PLoS ONE, 2022, 17, e0264508.	2.5	5
11	Exploring definitions of retention in care for people living with HIV in the United States in the modern treatment era. Aids, 2022, 36, 1181-1189.	2.2	2
12	Possible sex difference in latent tuberculosis infection risk among close tuberculosis contacts. International Journal of Infectious Diseases, 2022, 122, 685-692.	3.3	2
13	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005–2015. Journal of Infectious Diseases, 2021, 223, 2113-2123.	4.0	12
14	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clinical Infectious Diseases, 2021, 73, e2234-e2242.	5.8	59
15	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens. Clinical Infectious Diseases, 2021, 73, e2153-e2163.	5.8	32
16	Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. Clinical Infectious Diseases, 2021, 72, 1910-1918.	5.8	6
17	Outcomes After Second-Line Antiretroviral Therapy in Children Living with HIV in Latin America. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 993-1001.	2.1	0
18	The Impact of State Mask-Wearing Requirements on the Growth of Coronavirus Disease 2019 Cases, Hospitalizations, and Deaths in the United States. Clinical Infectious Diseases, 2021, 73, 1703-1706.	5.8	14

Peter Francis Rebeiro

#	Article	IF	CITATIONS
19	Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open, 2021, 11, e044687.	1.9	36
20	Risk of HIV Diagnosis Following Bacterial Sexually Transmitted Infections in Tennessee, 2013–2017. Sexually Transmitted Diseases, 2021, 48, 873-880.	1.7	2
21	Development and Validation of a Multivariable Prediction Model for Missed HIV Health Care Provider Visits in a Large US Clinical Cohort. Open Forum Infectious Diseases, 2021, 8, ofab130.	0.9	5
22	Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study. Lancet HIV,the, 2021, 8, e266-e273.	4.7	32
23	Timing of HIV diagnosis relative to pregnancy and postpartum HIV care continuum outcomes among Latin American women, 2000 to 2017. Journal of the International AIDS Society, 2021, 24, e25740.	3.0	2
24	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. Annals of Internal Medicine, 2021, 174, 1197-1206.	3.9	31
25	Achieving consistency in measures of HIVâ€1 viral suppression across countries: derivation of an adjustment based on international antiretroviral treatment cohort data. Journal of the International AIDS Society, 2021, 24, e25776.	3.0	2
26	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases, 2021, 73, e2334-e2337.	5.8	8
27	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. Journal of Infectious Diseases, 2021, 224, 657-666.	4.0	3
28	53. Sex and Race Disparities in Premature Mortality among People with HIV: A 21-Year Observational Cohort Study. Open Forum Infectious Diseases, 2021, 8, S37-S37.	0.9	0
29	51. Patient Reported Outcomes Collection: A Mixed Methods Study at an urban HIV Clinic associated with a Historically Black Medical College in the Southern United States. Open Forum Infectious Diseases, 2021, 8, S35-S36.	0.9	0
30	Visualizing the geography of HIV observational cohorts with density-adjusted cartograms. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	2.1	1
31	Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 1267-1274.	5.8	218
32	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. Clinical Infectious Diseases, 2020, 70, 1131-1138.	5.8	26
33	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases, 2020, 70, 1176-1185.	5.8	27
34	The Population Impact of Late Presentation With Advanced HIV Disease and Delayed Antiretroviral Therapy in Adults Receiving HIV Care in Latin America. American Journal of Epidemiology, 2020, 189, 564-572.	3.4	19
35	Mood Disorders and Increased Risk of Noncommunicable Disease in Adults With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 397-404.	2.1	10
36	Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. Journal of Infectious Diseases, 2020, 221, 1416-1424.	4.0	6

#	Article	IF	CITATIONS
37	Clinic-Level Factors Associated With Retention in Care Among People Living With Human Immunodeficiency Virus in a Multisite US Cohort, 2010–2016. Clinical Infectious Diseases, 2020, 71, 2592-2598.	5.8	5
38	Implications of COVIDâ€19 for HIV Research: data sources, indicators and longitudinal analyses. Journal of the International AIDS Society, 2020, 23, e25627.	3.0	10
39	RE: Role of rapid diagnostics for viral respiratory infections in antibiotic prescribing decision in the emergency department, by Li et al (2019). Infection Control and Hospital Epidemiology, 2020, 41, 991-992.	1.8	1
40	Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases, 2020, 73, e1408-e1414.	5.8	6
41	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. Epidemiology, 2020, 31, 704-712.	2.7	8
42	Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. BMC Public Health, 2020, 20, 897.	2.9	8
43	Weight gain among treatmentâ€naÃ⁻ve persons with HIV starting integrase inhibitors compared to nonâ€nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Journal of the International AIDS Society, 2020, 23, e25484.	3.0	148
44	Tennessee Healthcare Provider Practices, Attitudes, and Knowledge Around HIV Pre-Exposure Prophylaxis. Journal of Primary Care and Community Health, 2020, 11, 215013272098441.	2.1	12
45	1421. Assessing Serious Infections Common in Persons Who Inject Drugs in the United States and Tennessee. Open Forum Infectious Diseases, 2020, 7, S717-S718.	0.9	Ο
46	475. Describing the impact of the COVID-19 pandemic on HIV care in Latin America. Open Forum Infectious Diseases, 2020, 7, S303-S304.	0.9	4
47	Trends and Disparities in Mortality and Progression to AIDS in the Highly Active Antiretroviral Therapy Era: Tennessee, 1996–2016. American Journal of Public Health, 2019, 109, 1266-1272.	2.7	2
48	Temporal Trends and Sociodemographic Correlates of PrEP Uptake in Tennessee, 2017. AIDS and Behavior, 2019, 23, 304-312.	2.7	11
49	3309 Clinic-Level Factors and Retention in Care among People Living with HIV (PLWH) in a United States (US) Multi-Site Cohort, 2010-2016. Journal of Clinical and Translational Science, 2019, 3, 85-86.	0.6	Ο
50	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal of Epidemiology, 2019, 188, 2097-2109.	3.4	32
51	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low―and middleâ€income countries: a multicohort study. Journal of the International AIDS Society, 2019, 22, e25392.	3.0	24
52	Changes in rapid HIV treatment initiation after national "treat all―policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. PLoS Medicine, 2019, 16, e1002822.	8.4	53
53	3166 Association between HIV and early weight loss and the impact on subsequent treatment outcomes among patients with tuberculosis. Journal of Clinical and Translational Science, 2019, 3, 34-34.	0.6	0
54	Increased vitamin D receptor expression from macrophages after stimulation with M. tuberculosis among persons who have recovered from extrapulmonary tuberculosis. BMC Infectious Diseases, 2019, 19, 366.	2.9	35

#	Article	IF	CITATIONS
55	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV,the, 2019, 6, e240-e249.	4.7	46
56	Methodologic Considerations for Small Cohort Studies. Clinical Infectious Diseases, 2019, 69, 1644-1644.	5.8	2
57	Substance Use, Demographic and Socioeconomic Factors Are Independently Associated With Postpartum HIV Care Engagement in the Southern United States, 1999–2016. Open Forum Infectious Diseases, 2019, 6, ofz023.	0.9	3
58	Viral suppression among persons in HIV care in the United States during 2009–2013: sampling bias in Medical Monitoring Project surveillance estimates. Annals of Epidemiology, 2019, 31, 3-7.	1.9	7
59	1286. Healthcare Provider Attitudes and Knowledge Around Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV-Infection in Tennessee. Open Forum Infectious Diseases, 2019, 6, S463-S463.	0.9	0
60	Temporal changes in ART initiation in adults with high CD4 counts in Latin America: a cohort study. Journal of the International AIDS Society, 2019, 22, e25413.	3.0	4
61	Global variations in mortality in adults after initiating antiretroviral treatment. Aids, 2019, 33, S283-S294.	2.2	16
62	The impact of data quality and source data verification on epidemiologic inference: a practical application using HIV observational data. BMC Public Health, 2019, 19, 1748.	2.9	11
63	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. Clinical Infectious Diseases, 2019, 68, 795-802.	5.8	13
64	Human Immunodeficiency Virus (HIV) Viral Suppression After Transition From Having No Healthcare Coverage and Relying on Ryan White HIV/AIDS Program Support to Medicaid or Private Health Insurance. Clinical Infectious Diseases, 2019, 69, 538-541.	5.8	21
65	Medically Attended Catheter Complications Are Common in Patients With Outpatient Central Venous Catheters. Infection Control and Hospital Epidemiology, 2018, 39, 439-444.	1.8	6
66	Tennessee's In-state Vulnerability Assessment for a "Rapid Dissemination of Human Immunodeficiency Virus or Hepatitis C Virus Infection―Event Utilizing Data About the Opioid Epidemic. Clinical Infectious Diseases, 2018, 66, 1722-1732.	5.8	22
67	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2018, 66, 1230-1238.	5.8	131
68	Impact of Culture-Independent Diagnostic Testing on Recovery of Enteric Bacterial Infections. Clinical Infectious Diseases, 2018, 66, 1892-1898.	5.8	25
69	The relationship between adverse neighborhood socioeconomic context and HIV continuum of care outcomes in a diverse HIV clinic cohort in the Southern United States. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1426-1434.	1.2	27
70	Health Literacy and Demographic Disparities in HIV Care Continuum Outcomes. AIDS and Behavior, 2018, 22, 2604-2614.	2.7	26
71	Evaluating the care cascade after antiretroviral therapy initiation in Latin America. International Journal of STD and AIDS, 2018, 29, 4-12.	1.1	12
72	Use of Social Network Strategy Among Young Black Men Who Have Sex With Men for HIV Testing, Linkage to Care, and Reengagement in Care, Tennessee, 2013-2016. Public Health Reports, 2018, 133, 43S-51S.	2.5	17

PETER FRANCIS REBEIRO

#	Article	IF	CITATIONS
73	Letter to the Editor. Tuberculosis, 2018, 113, 122-124.	1.9	0
74	Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex and Sexual Mode of HIV Acquisition on HIV Survival in the Americas. AIDS Patient Care and STDs, 2018, 32, 306-313.	2.5	4
75	HIV-1 Transmission Clustering and Phylodynamics Highlight the Important Role of Young Men Who Have Sex with Men. AIDS Research and Human Retroviruses, 2018, 34, 879-888.	1.1	27
76	Is substance use associated with HIV cascade outcomes in Latin America?. PLoS ONE, 2018, 13, e0194228.	2.5	11
77	leDEA-WHO Research-Policy Collaboration: contributing real-world evidence to HIV progress reporting and guideline development. Journal of Virus Eradication, 2018, 4, 9-15.	0.5	15
78	First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. Clinical Infectious Diseases, 2017, 64, ciw804.	5.8	37
79	Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care and STDs, 2017, 31, 129-144.	2.5	50
80	A Flow-Based Model of the HIV Care Continuum in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 548-553.	2.1	20
81	New Faces of HIV Infection: Age, Race, and Timing of Entry into HIV Care in the Southeastern United States. Journal of the International Association of Providers of AIDS Care, 2017, 16, 347-352.	1.5	8
82	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	5.8	44
83	Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 527-531.	2.1	222
84	Brief Report: Assessing and Interpreting the Association Between Continuous Covariates and Outcomes in Observational Studies of HIV Using Splines. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e60-e63.	2.1	46
85	A Pragmatic Approach for Reproducible Research With Sensitive Data. American Journal of Epidemiology, 2017, 186, 387-392.	3.4	20
86	Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care. AIDS and Behavior, 2017, 21, 1996-2004.	2.7	28
87	Trends in HIV Continuum of Care Outcomes over Ten Years of Follow-Up at a Large HIV Primary Medical Home in the Southeastern United States. AIDS Research and Human Retroviruses, 2017, 33, 1027-1034.	1.1	12
88	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clinical Infectious Diseases, 2017, 65, 636-643.	5.8	67
89	Observational Study of the Effect of Patient Outreach on Return to Care: The Earlier the Better. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 141-148.	2.1	11
90	Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens. Open Forum Infectious Diseases, 2017, 4, S433-S433.	0.9	1

#	Article	IF	CITATIONS
91	Association Between Patient Portal Access and Viral Suppression Among People Living with HIV in a Large Southeastern Clinical Cohort. Open Forum Infectious Diseases, 2017, 4, S40-S40.	0.9	1
92	A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NAâ€ACCORD and CCASAnet clinical cohorts. Journal of the International AIDS Society, 2016, 19, 20707.	3.0	8
93	Health outcomes among HIVâ€positive Latinos initiating antiretroviral therapy in North America versus Central and South America. Journal of the International AIDS Society, 2016, 19, 20684.	3.0	8
94	Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression. Journal of the International AIDS Society, 2016, 19, 20636.	3.0	14
95	Interactive Data Visualization for HIV Cohorts: Leveraging Data Exchange Standards to Share and Reuse Research Tools. PLoS ONE, 2016, 11, e0151201.	2.5	6
96	Racial and Ethnic Disparities in Hospital Readmissions After Delivery. Obstetrics and Gynecology, 2016, 127, 799.	2.4	0
97	Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 102-110.	2.1	8
98	The 2013 HIV Continuum of Care in Tennessee. Public Health Reports, 2016, 131, 695-703.	2.5	11
99	Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America. AIDS and Behavior, 2016, 20, 2692-2699.	2.7	28
100	Improving HIV Surveillance Among Transgender Populations in Tennessee. LGBT Health, 2016, 3, 208-213.	3.4	3
101	Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 197-204.	2.1	31
102	Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS ONE, 2016, 11, e0146119.	2.5	47
103	The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2016, 40, 448-454.	1.1	1
104	CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean. Open Forum Infectious Diseases, 2015, 2, ofv079.	0.9	8
105	Risk Prediction Tool for Medical Appointment Attendance Among HIV-Infected Persons with Unsuppressed Viremia. AIDS Patient Care and STDs, 2015, 29, 240-247.	2.5	14
106	Impact of Age on Retention in Care and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 413-419.	2.1	89
107	Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. American Journal of Epidemiology, 2015, 182, 952-960.	3.4	22
108	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	5.8	142

Peter Francis Rebeiro

#	Article	IF	CITATIONS
109	Strong Agreement of Nationally Recommended Retention Measures from the Institute of Medicine and Department of Health and Human Services. PLoS ONE, 2014, 9, e111772.	2.5	27
110	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. Clinical Infectious Diseases, 2014, 58, 1185-1189.	5.8	65
111	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. Journal of Infectious Diseases, 2013, 208, 1240-1249.	4.0	43
112	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	5.8	90
113	Retention Among North American HIV-Infected Persons in Clinical Care, 2000–2008. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 356-362.	2.1	131
114	Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons. Clinical Nephrology, 2013, 79, 93-100.	0.7	3
115	Hemoglobin May Contribute to Sex Differences in Mortality among HIV-Infected Persons in Care. PLoS ONE, 2012, 7, e44999.	2.5	11
116	U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008. Annals of Internal Medicine, 2012, 157, 325.	3.9	106
117	Virologic, Immunologic and Clinical Responses in Foreign-Born versus US-Born HIV-1 Infected Adults Initiating Antiretroviral Therapy: An Observational Cohort Study. PLoS ONE, 2012, 7, e52336.	2.5	4
118	The relationship between injection and noninjection drug use and HIV disease progression. Journal of Substance Abuse Treatment, 2011, 41, 14-20.	2.8	17
119	Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two U.S. Clinic Cohorts. PLoS ONE, 2011, 6, e18462.	2.5	43
120	Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. Aids, 2011, 25, 1471-1479.	2.2	47
121	Tuberculosis Risk Before and After Highly Active Antiretroviral Therapy Initiation: Does HAART Increase the Short-Term TB Risk in a Low Incidence TB Setting?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 305-310.	2.1	13
122	Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy. Epidemiology, 2010, 21, 698-705.	2.7	14
123	Race, Kidney Disease Progression, and Mortality Risk in HIV-Infected Persons. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2269-2275.	4.5	20
124	Postpartum Discontinuation of Antiretroviral Therapy and Risk of Maternal AIDS-Defining Events, Non-AIDS–Defining Events, and Mortality Among a Cohort of HIV-1–Infected Women in the United States. AIDS Patient Care and STDs, 2010, 24, 279-286.	2.5	31
125	Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response. PLoS ONE, 2009, 4, e6961.	2.5	15
126	Reply to Amendola et al Clinical Infectious Diseases, 2009, 48, 1631-1632.	5.8	1

8

#	Article	IF	CITATIONS
127	Race and Sex Differences in Antiretroviral Therapy Use and Mortality among HIVâ€Infected Persons in Care. Journal of Infectious Diseases, 2009, 199, 991-998.	4.0	101
128	Increased Detectability of Plasma HIVâ€1 RNA after Introduction of a New Assay and Altered Specimenâ€Processing Procedures. Clinical Infectious Diseases, 2008, 47, 1354-1357.	5.8	28
129	Misdiagnosis of HIV infection: implications for universal testing. Aids, 2008, 22, 546-547.	2.2	2
130	Pregnancy and HIV Disease Progression during the Era of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 196, 1044-1052.	4.0	71
131	Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity. Clinical Infectious Diseases, 2006, 43, 779-782.	5.8	91
132	CD4 Lymphocyte Percentage Predicts Disease Progression in HIVâ€Infected Patients Initiating Highly Active Antiretroviral Therapy with CD4 Lymphocyte Counts >350 Lymphocytes/mm3. Journal of Infectious Diseases, 2005, 192, 950-957.	4.0	52
133	Oxidant Stress Is Increased during Treatment of Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2003, 37, 1711-1717.	5.8	105
134	Implications of T-Cell P-Glycoprotein Activity During HIV-1 Infection and Its Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 119-126.	2.1	19